• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Investigation of Copper-64-Based Host-Guest Chemistry Pretargeted Positron Emission Tomography.基于铜-64 的主体-客体化学 Pretargeted 正电子发射断层扫描研究。
Mol Pharm. 2022 Jul 4;19(7):2268-2278. doi: 10.1021/acs.molpharmaceut.2c00102. Epub 2022 Jun 14.
2
Pretargeting with Cucurbituril-Adamantane Host-Guest Pair in Xenograft Models.葫芦脲-金刚烷主体客体对在异种移植模型中的前靶向作用。
J Nucl Med. 2023 Aug;64(8):1203-1209. doi: 10.2967/jnumed.122.265008. Epub 2023 Apr 6.
3
Cucurbituril-Ferrocene: Host-Guest Based Pretargeted Positron Emission Tomography in a Xenograft Model.葫芦脲-二茂铁:异种移植模型基于主体-客体的正电子发射断层显像术的前药。
Bioconjug Chem. 2021 Aug 18;32(8):1554-1558. doi: 10.1021/acs.bioconjchem.1c00280. Epub 2021 Jun 22.
4
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.胰腺癌的预靶向免疫正电子发射断层显像:克服循环抗原和内化抗体以降低辐射剂量
J Nucl Med. 2016 Mar;57(3):453-9. doi: 10.2967/jnumed.115.163824. Epub 2015 Oct 15.
5
Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.通过调节放射性配体药代动力学优化用于结直肠癌PET成像的预靶向策略
Mol Pharm. 2015 Oct 5;12(10):3575-87. doi: 10.1021/acs.molpharmaceut.5b00294. Epub 2015 Aug 31.
6
A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.基于生物正交 Diels-Alder 点击化学的靶向 PET 成像策略。
J Nucl Med. 2013 Aug;54(8):1389-96. doi: 10.2967/jnumed.112.115840. Epub 2013 May 24.
7
Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with Zr-Labeled Anti-CD11b Positron Emission Tomography Imaging.基于生物正交 Diels-Alder 点击化学的靶向成像策略在胃癌中浸润性髓样细胞的靶向作用及其与 Zr 标记的抗 CD11b 正电子发射断层扫描成像的比较。
Mol Pharm. 2022 Jan 3;19(1):246-257. doi: 10.1021/acs.molpharmaceut.1c00745. Epub 2021 Nov 24.
8
Dual Radionuclide Theranostic Pretargeting.双重放射性核素治疗性靶向预定位。
Mol Pharm. 2019 Oct 7;16(10):4416-4421. doi: 10.1021/acs.molpharmaceut.9b00746. Epub 2019 Sep 9.
9
Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice.使用64Cu标记的癌胚抗原(CEA)抗体在转基因小鼠中通过正电子发射断层扫描(PET)对肝转移灶进行放射免疫显像。
PLoS One. 2014 Sep 16;9(9):e106921. doi: 10.1371/journal.pone.0106921. eCollection 2014.
10
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Zr- and Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.用于多发性骨髓瘤免疫 PET 的最佳放射性核素是什么?Zr 和 Cu 标记的抗 CD138 在临床前同种异体模型中的比较研究。
Int J Mol Sci. 2019 May 24;20(10):2564. doi: 10.3390/ijms20102564.

引用本文的文献

1
Challenges and Opportunities of Functionalized Cucurbiturils for Biomedical Applications.功能化葫芦脲在生物医学应用中的挑战与机遇
JACS Au. 2023 Aug 28;3(9):2356-2377. doi: 10.1021/jacsau.3c00273. eCollection 2023 Sep 25.
2
Recent Advances in Cu/Cu-Based Radiopharmaceuticals.最新的铜/铜基放射性药物进展。
Int J Mol Sci. 2023 May 23;24(11):9154. doi: 10.3390/ijms24119154.
3
Pretargeting with Cucurbituril-Adamantane Host-Guest Pair in Xenograft Models.葫芦脲-金刚烷主体客体对在异种移植模型中的前靶向作用。
J Nucl Med. 2023 Aug;64(8):1203-1209. doi: 10.2967/jnumed.122.265008. Epub 2023 Apr 6.

本文引用的文献

1
Cucurbituril-Ferrocene: Host-Guest Based Pretargeted Positron Emission Tomography in a Xenograft Model.葫芦脲-二茂铁:异种移植模型基于主体-客体的正电子发射断层显像术的前药。
Bioconjug Chem. 2021 Aug 18;32(8):1554-1558. doi: 10.1021/acs.bioconjchem.1c00280. Epub 2021 Jun 22.
2
Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.临床预靶向放射免疫成像与治疗的现状
J Nucl Med. 2021 Sep 1;62(9):1200-1206. doi: 10.2967/jnumed.120.260687. Epub 2021 May 20.
3
Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses.使用 Ac-proteus-DOTA 的阿尔法放射免疫疗法治疗实体瘤 - 治愈剂量下的安全性。
Theranostics. 2020 Sep 14;10(25):11359-11375. doi: 10.7150/thno.48810. eCollection 2020.
4
Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.针对肽核酸介导的放射性核素 HER2 前靶向,将识别标签定点连接到曲妥珠单抗上。
Biomaterials. 2019 May;203:73-85. doi: 10.1016/j.biomaterials.2019.02.012. Epub 2019 Feb 14.
5
Leveraging Bioorthogonal Click Chemistry to Improve Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.利用生物正交点击化学提高胰腺导管腺癌的 Ac-放射性免疫治疗。
Clin Cancer Res. 2019 Jan 15;25(2):868-880. doi: 10.1158/1078-0432.CCR-18-1650. Epub 2018 Oct 23.
6
Supramolecular complexes for nanomedicine.用于纳米医学的超分子复合物。
Bioorg Med Chem Lett. 2018 Nov 1;28(20):3290-3301. doi: 10.1016/j.bmcl.2018.09.015. Epub 2018 Sep 13.
7
Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines.核医学成像和放射性核素治疗中的前靶向:提高治疗和纳米医学的疗效。
Biomaterials. 2018 Oct;179:209-245. doi: 10.1016/j.biomaterials.2018.06.021. Epub 2018 Jun 22.
8
Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.单克隆抗体药代动力学及其在早期开发中的考虑因素教程。
Clin Transl Sci. 2018 Nov;11(6):540-552. doi: 10.1111/cts.12567. Epub 2018 Aug 7.
9
Pretargeting for imaging and therapy in oncological nuclear medicine.肿瘤核医学中成像与治疗的预靶向技术
EJNMMI Radiopharm Chem. 2017;2(1):6. doi: 10.1186/s41181-017-0026-8. Epub 2017 Jun 6.
10
Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma.点击介导的结直肠癌 Pretargeted 放射免疫治疗。
Mol Pharm. 2018 Apr 2;15(4):1729-1734. doi: 10.1021/acs.molpharmaceut.8b00093. Epub 2018 Mar 8.

基于铜-64 的主体-客体化学 Pretargeted 正电子发射断层扫描研究。

Investigation of Copper-64-Based Host-Guest Chemistry Pretargeted Positron Emission Tomography.

机构信息

Department of Radiology, Stony Brook University, Stony Brook, New York 11794, United States.

Chemical and Physical Biology Graduate Program, Vanderbilt University, Nashville, Tennessee 37232, United States.

出版信息

Mol Pharm. 2022 Jul 4;19(7):2268-2278. doi: 10.1021/acs.molpharmaceut.2c00102. Epub 2022 Jun 14.

DOI:10.1021/acs.molpharmaceut.2c00102
PMID:35700402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11271262/
Abstract

Pretargeting is a technique that uses macromolecules as targeting agents for nuclear imaging and therapy with the goal of reducing the radiation toxicity to healthy tissues often associated with directly radiolabeled macromolecules. In pretargeting, a macromolecule is radiolabeled at the target site using a radiolabeled small molecule (radioligand) that interacts with the macromolecule with high specificity. We report an investigation of host-guest chemistry-driven pretargeting using copper-64 radiolabeled ferrocene (Fc; guest) compounds and a cucurbit[7]uril (CB7; host) molecule functionalized carcinoembryonic antigen targeting hT84.66-M5A monoclonal antibody (CB7-M5A). Two novel ferrocene-based radioligands ([Cu]Cu-NOTA-PEG-Fc and [Cu]Cu-NOTA-PEG-Fc) were prepared, and their stability, pharmacokinetic profile in healthy mice, and pretargeting performance in a subcutaneous BxPC3 human pancreatic cancer cell xenograft mouse model were compared. The antibody dosing was optimized using a zirconium-89 radiolabeled M5A antibody ([Zr]Zr-DFO-M5A) in a BxPC3 xenograft model, and the dosimetry of [Zr]Zr-DFO-M5A and the pretargeting approach were compared. Finally, the effects of varying lag times up to 9 days between CB7-M5A and radioligand injection were investigated. pretargeting studies with both ferrocene radioligands resulted in specific tumor uptake ( = 0.0006 and = 0.003) and also showed that the host-guest-based pretargeting approach excels with extended lag times up to 9 days with good tumor localization, suggesting that host-guest pretargeting may be suitable for use without clearing agents which have complicated clinical application of this technique. To our knowledge, the reported lag time of 9 days is the longest investigated lag time in any reported pretargeting studies.

摘要

前靶向是一种利用大分子作为核成像和治疗的靶向剂的技术,目的是降低与直接放射性标记大分子相关的健康组织的辐射毒性。在前靶向中,使用与大分子具有高特异性相互作用的放射性标记小分子(放射性配体)在靶位标记大分子。我们报告了使用铜-64 放射性标记的二茂铁(Fc;客体)化合物和葫芦[7]脲(CB7;主体)分子功能化癌胚抗原靶向 hT84.66-M5A 单克隆抗体(CB7-M5A)进行主体-客体化学驱动的前靶向研究。制备了两种新型基于二茂铁的放射性配体([Cu]Cu-NOTA-PEG-Fc 和 [Cu]Cu-NOTA-PEG-Fc),并比较了它们在健康小鼠中的稳定性、药代动力学特征以及在皮下 BxPC3 人胰腺癌细胞异种移植小鼠模型中的前靶向性能。使用锆-89 放射性标记的 M5A 抗体 ([Zr]Zr-DFO-M5A) 在 BxPC3 异种移植模型中优化了抗体剂量,并比较了 [Zr]Zr-DFO-M5A 的剂量学和前靶向方法。最后,研究了 CB7-M5A 和放射性配体之间的滞后时间长达 9 天变化对前靶向的影响。两种二茂铁放射性配体的前靶向研究均导致肿瘤摄取特异性(=0.0006 和=0.003),并且还表明基于主体-客体的前靶向方法具有长达 9 天的延长滞后时间的优势,具有良好的肿瘤定位,这表明主体-客体前靶向可能适合在不使用清除剂的情况下使用,清除剂的临床应用复杂。据我们所知,报告的 9 天滞后时间是任何报道的前靶向研究中最长的滞后时间。